ANDA 76826, held by Watson Labs Teva. Levofloxacin.
As of Nov 16, 2026, ANDA 76826 (Levofloxacin), held by Watson Labs Teva, was first approved by FDA on Feb 10, 2011, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 10, 2011 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Levofloxacin0.5% · solution/drops;ophthalmic | Levofloxacin | Discontinued |
| Jul 13, 2017 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 10, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters